Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19) trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (1 shown)

CompletedPhase 1

NCT05091723

TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation

This is a Phase 1 pharmacokinetic (PK) study in healthy participants to assess the plasma pharmacokinetics, safety, and tolerability of a single inhaled dose of…

United States14 participantsStarted 2021-10-13

Treatment: Nezulcitinib (TD-0903) Dose A, Nezulcitinib (TD-0903) Dose B